Federal Register Notices
View Federal Register notices of proposed exclusive licenses. Clicking on the "View" links will display the Federal Register Notice in a new tab. You can also search directly on the Federal Register site.
| View | Date Published | Title | Comments Close On | Dates |
|---|---|---|---|---|
| View | Prospective Grant of Exclusive License: “High Throughput Infrared Spectroscopy" | Only written comments and/or applications for a license that are received by the NIH Office of Technology Transfer on or before September 9, 2002, will be considered. | ||
| View | Prospective Grant of Exclusive License: “Compound, Composition and Method For Treating Cancer”, U.S. Patent 6,235,761 | Only written comments and/or license applications that are received by the National Institutes of Health on or before August 9, 2002 will be considered. | ||
| View | Prospective Grant of Exclusive License: Systems and Methods for Aerosol Delivery of Agents | 03/15/01. | ||
| View | Prospective Grant of Exclusive License: Adult Human Dental Pulp Stem Cells In Vitro and In Vivo | Only written comments and/or application for a license, which are received by the NIH Office of Technology Transfer on or before July 29, 2002 will be considered. | ||
| View | Opportunity for Cooperative Research and Development Agreement(s) (CRADAs) and/or License(s) for the Development and Commercialization of Nitric Oxide-Releasing Drugs and Biomaterials | Confidential CRADA proposal summaries, preferably one page or less, and a signed Confidential Disclosure Agreement (CDA) (http:// ttb.nci.nih.gov/forms.html) must be submitted to the NCI Technology Transfer Branch (TTB) on or before June 24, 2002, to take full advantage of this opportunity. CRADA proposal summaries submitted thereafter may be considered if a suitable CRADA Collaborator is not selected from among the timely responses. Guidelines for preparing a full CRADA proposal will be communicated shortly thereafter to all respondents with whom initial confidential discussions will have established sufficient mutual interest. | ||
| View | Prospective Grant of Exclusive License: Treatment of Central Nervous System Disorders With a Combination of Dopaminergic and Adrenergic Antagonists | Only written comments and/or applications for a license which are received by the NIH Office of Technology Transfer on or before July 22, 2002, will be considered. | ||
| View | Prospective Grant of Exclusive License: Adenosine A3 Agonists for Use as Therapeutic Agents | Only written comments and/or applications for a license which are received by the NIH Office of Technology Transfer on or before July 22, 2002, will be considered. | ||
| View | Prospective Grant of Exclusive License: Control of Arthropod Vectors of Parasitic Diseases | 06/ 16/00 | ||
| View | Prospective Grant of Exclusive License: Delivery of Pigment Epithelium Derived Factor (PEDF) To Treat Cancer by Gene Therapy | Only written comments and/or application for a license which are received by the NIH Office of Technology Transfer on or before July 1, 2002, will be considered. | ||
| View | Prospective Grant of Exclusive License: Treatment of Ocular Disease With Pigment Epithelium Derived Factor (PEDF) Protein Using Non-Gene Therapy Means | Only written comments and/or application for a license which are received by the NIH Office of Technology Transfer on or before July 1, 2002, will be considered. | ||
| View | Prospective Grant of Exclusive License: 1,8 Naphthalimide Imidazo [4,5,1-de] Acridones With Anti-Tumor Activity | Only written comments and/or application for a license which are received by the NIH Office of Technology Transfer on or before July 1, 2002, will be considered. | ||
| View | Prospective Grant of Exclusive License: Targeted Gene Expression for the Treatment of Cancer, Bone Metastasis and Diabetes | Only written comments and/or applications for a license, received by the NIH Office of Technology Transfer on or before June 24, 2002, will be considered. | ||
| View | Prospective Grant of Exclusive License: Synthetic Ordered Arrays of Antigen for the Induction of Autoantibodies | Only written comments and/or application for a license which are received by the NIH Office of Technology Transfer on or before June 24, 2002, will be considered. | ||
| View | Government-Owned Inventions; Availability for Licensing | |||
| View | Prospective Grant of Exclusive License: Glycoprotein Hormone Superagonists | Only written comments and/or application for a license, which are received by the NIH Office of Technology Transfer on or before June 14, 2002, will be considered. | ||
| View | Prospective Grant of Exclusive License: The Use of Macrocyclic Lactones as Inhibitors of Vacuolar-Type ATPases for the Treatment of Cancer | Only written comments and/or application for a license which are received by the NIH Office of Technology Transfer on or before May 24, 2002, will be considered. | ||
| View | Prospective Grant of Co-Exclusive License: “Cloning and Expression of cDNA for Human Dihydropyrimidine Dehydrogenase” | Only written comments and/or license applications which are received by the National Institutes of Health on or before May 17, 2002, will be considered. | ||
| View | Prospective Grant of Co-Exclusive License: Human Derived Monocyte Attracting Purified Peptide Products for Treating Human Infections and Neoplasms in a Human Body | Only written comments and/or license applications which are received by the National Institutes of Health on or before May 13, 2002, will be considered. | ||
| View | Prospective Grant of Exclusive License: Uses of Cyanovirin-N for HIV Vaccines | Only written comments and/or applications for a license which are received by the NIH Office of Technology Transfer on or before May 13, 2002, will be considered. | ||
| View | Prospective Grant of Exclusive License: Growing Ehrlichia Species in a Continuous Cell Line | 05/03/90. | ||
| View | Prospective Grant of Exclusive License: Vaccines and Diagnostic Tests for Cat Scratch Fever | 01/17/92. | ||
| View | Prospective Grant of Exclusive License: The Use of Geldanamycin and Its Derivatives for the Treatment of Cancer | Only written comments and/or application for a license which are received by the NIH Office of Technology Transfer on or before May 3, 2002, will be considered. | ||
| View | Prospective Grant of Exclusive License: Gossypol, Gossypol Acetic Acid and Derivatives Thereof and the Use Thereof for Treating Cancer | Only written comments and/or application for a license which are received by the NIH Office of Technology Transfer on or before May 3, 2002, will be considered. | ||
| View | Prospective Grant Of Exclusive License: Prophylactic and/or Therapeutic Vaccine Against Pseudomonas aeruginosa, Chlamydia trachomatis and Mycoplasma pneumonia, Influenza virus, Nisseria gonorrhea and Vibrio cholerae | Only written comments and/or applications for a license, which are received by the NIH Office of Technology Transfer on or before April 15, 2002, will be considered. | ||
| View | Government-Owned Inventions; Availability for Licensing |